Nurix Therapeutics, Inc. NRIX Collaboration revenue — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s collaboration revenue — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s collaboration revenue — revenue?
- Nurix Therapeutics, Inc. (NRIX) reported collaboration revenue — revenue of $6.25M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s collaboration revenue — revenue changed year-over-year?
- Nurix Therapeutics, Inc.'s collaboration revenue — revenue decreased by 66.1% year-over-year, from $18.45M to $6.25M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s collaboration revenue — revenue?
- Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s collaboration revenue — revenue has grown at a 11.8% compound annual growth rate (CAGR), from $38.63M to $53.98M.
- What does collaboration revenue — revenue mean?
- This metric represents the revenue recognized from strategic partnerships, research collaborations, and licensing agreements with other biopharmaceutical entities. It reflects the company's ability to monetize its proprietary drug discovery platforms and pipeline assets through milestone payments, upfront fees, and cost-sharing arrangements. This revenue stream is a critical indicator of the company's external validation and its capacity to fund internal R&D efforts through non-dilutive capital.